Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
June 29, 2021 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., June 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and...
Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan
June 24, 2021 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., June 24, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and...
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
June 01, 2021 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:01 ET
|
Brickell Biotech, Inc.
Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies...
Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
April 29, 2021 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
April 27, 2021 07:30 ET
|
Brickell Biotech, Inc.
Phase 3 Pivotal Cardigan II study exceeds 50% enrollment- - -Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021 BOULDER, Colo., April 27, 2021 ...
Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis
April 23, 2021 10:01 ET
|
Brickell Biotech, Inc.
Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity...
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX
April 16, 2021 10:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and...
Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology
April 15, 2021 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., April 15, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and...
Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 09, 2021 16:01 ET
|
Brickell Biotech, Inc.
Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis Cardigan I study...